Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Teva Pharmaceutical Industries Limited : The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Teva Pharmaceutical Industries Ltd. Shareholders and a Lead Plaintiff Deadline of October 23, 2017 (TEVA)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/04/2017 | 05:23pm CEST

NEW YORK, NY / ACCESSWIRE / October 4, 2017 / The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) who purchased American Depositary Shares between November 15, 2016 and August 2, 2017. The action, which was filed in the United States District Court for the Eastern District of Pennsylvania, alleges that the Company violated federal securities laws.

In particular, the complaint alleges that, throughout the Class Period, Defendants issued materially false and/or misleading statements and/or failed to disclose adverse information concerning the Company's business and outlook. In particular, it is alleged that Teva failed to disclose and/or omitted the true negative impact of the acquisition and integration of Actavis Generics on the Company's financial results and business prospects.

Shareholders have until October 23, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.

If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sbm/teva-pharmaceutical-industries-ltd?wire=1.

Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm


© Accesswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
08/17TEVA PHARMACEUTICAL INDUSTRIES : jumps on FDA approval for generic EpiPen
AQ
08/17TODAY’S RESEARCH REPORTS ON STOCKS T : Teva Pharmaceutical and Mylan
AC
08/17REGENERON PHARMACEUTICALS : Teva reports positive results on Phase III chronic p..
AQ
08/17REGENERON PHARMACEUTICALS : and Teva Announce Positive Topline Phase 3 Fasinumab..
AQ
08/16TEVA PHARMACEUTICAL INDUSTRIES : Antares Pharma Shares Rise After FDA Approves F..
DJ
08/16TEVA PHARMACEUTICAL INDUSTRIES : Researchers from Teva Pharmaceutical Report New..
AQ
08/16BERKSHIRE HATHAWAY : Buffett`s Berkshire Hathaway again increases Teva stake
AQ
08/16REGENERON PHARMACEUTICALS : Teva Report Positive Phase 3 Fasinumab Results
DJ
08/16TEVA PHARMACEUTICAL INDUSTRIES : and Regeneron Announce Positive Topline Phase 3..
BU
08/15BERKSHIRE HATHAWAY : Buffett's Berkshire Hathaway again increases Teva stake
AQ
More news
News from SeekingAlpha
07/11YOUR DAILY PHARMA SCOOP : IsoRay Doubles, OncoCyte Zooms, Celgene Sluggish 
07/11Big Pharma in the red after Pfizer backs away from price hikes 
07/10Pricing transparency law in California having effect, drug makers nix planned.. 
07/10Crinetics Pharmaceuticals Readies $80 Million IPO 
07/09Biotechs give up gains after Trump tweet on prices 
Financials ($)
Chart TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Duration : Period :
Teva Pharmaceutical Industries Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TEVA PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 19,5 $
Spread / Average Target -15%
Managers
NameTitle
Kåre Schultz President, Chief Executive Officer & Director
Sol J. Barer Chairman
Carlo de Notaristefani Executive Vice President-Global Operations
Michael McClellan Chief Financial Officer & Executive Vice President
Amir Elstein Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED28.32%22 323
JOHNSON & JOHNSON-5.18%347 417
PFIZER14.36%238 136
NOVARTIS-0.83%207 488
ROCHE HOLDING LTD.-2.96%206 696
MERCK AND COMPANY22.36%176 752